New Jersey Cannabis Market: Regulations, Dispensaries & Industry Growth

Executive Summary

New Jersey's adult-use cannabis market, which launched in April 2022, has evolved into a $1.9 billion annual industry serving over 2 million registered consumers across 146 licensed dispensaries as of May 2026. The Garden State's regulatory framework, administered by the New Jersey Cannabis Regulatory Commission (CRC), operates under the Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (CREAMMA), signed into law on February 22, 2021. Recent developments highlight growing competitive tensions in the wholesale supply chain, with Elmwood Park-based operators alleging anticompetitive practices by Hackensack competitors in May 2026. The market faces ongoing challenges including federal Schedule I classification under 21 U.S.C. § 812, limited banking access, Internal Revenue Code Section 280E tax burdens, and interstate commerce restrictions. New Jersey's vertically integrated license structure, social equity provisions, and municipal opt-in requirements have created a complex landscape where 321 of 565 municipalities have authorized cannabis operations, generating over $387 million in cumulative tax revenue since launch. The state's medical program, operational since 2010, continues alongside adult-use sales with 136,000 active medical patients as of April 2026.

Why This Matters

New Jersey's cannabis market represents the largest regulated adult-use program in the densely populated Northeast corridor, with direct implications for 9.3 million residents and approximately 40 million people within a two-hour drive. The state's $1.9 billion annual market ranks sixth nationally by revenue, behind California, Michigan, Illinois, Colorado, and Arizona. For patients, the program provides legal access to 38 approved medical conditions including chronic pain, PTSD, anxiety, and cancer, with over 136,000 active medical marijuana cards issued as of April 2026. Multi-state operators (MSOs) including Curaleaf, Verano, Ascend Wellness, TerrAscend, and Acreage Holdings have invested over $800 million in New Jersey cultivation, processing, and retail infrastructure. The state's proximity to New York, Pennsylvania, and Connecticut markets makes it a strategic hub for regional expansion strategies, though interstate commerce remains federally prohibited under the Controlled Substances Act. Tax revenue flows directly to communities disproportionately impacted by cannabis prohibition. New Jersey's Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act allocates 70% of tax revenue to communities with arrest rates exceeding state averages, 20% to public health programs, and 10% to impaired driving enforcement. Through April 2026, the state collected $387 million in combined sales tax, excise tax, and municipal fees. For investors, New Jersey's market capitalization exceeds $2.3 billion across publicly traded and private operators. The state's license cap structure—initially limiting cultivation licenses to 37 entities and retail to geographic zones—has created significant enterprise value concentration. Wholesale cannabis prices declined from $3,800 per pound in April 2022 to $1,450 per pound in March 2026, compressing margins and intensifying competition for retail shelf space.

Background and History: From Prohibition to $1.9 Billion Market

New Jersey's path to legal cannabis spans 16 years from medical authorization to full adult-use implementation, marked by legislative battles, voter referendums, and regulatory buildout.

Medical Marijuana Foundations (2010-2019)

Governor Jon Corzine signed the Compassionate Use Medical Marijuana Act on January 18, 2010, making New Jersey the 14th state to legalize medical cannabis. The program launched with strict limitations: only six Alternative Treatment Centers (ATCs) initially licensed, a 12-condition qualifying list, and a two-ounce monthly purchase limit. The New Jersey Department of Health administered the program under regulations codified at N.J.A.C. 8:64. Early program enrollment remained low due to restrictive qualifying conditions and limited dispensary access. By December 2015, only 8,600 patients had enrolled across six operational ATCs. Governor Chris Christie's administration maintained conservative oversight, opposing expansion efforts throughout his tenure from 2010 to 2018.

Expansion and Legalization Push (2018-2020)

Governor Phil Murphy campaigned on adult-use legalization in 2017, taking office in January 2018 with legalization as a stated priority. The administration expanded the medical program significantly: increasing the monthly purchase limit to three ounces in July 2018, adding chronic pain and anxiety as qualifying conditions in March 2019, and authorizing 24 additional ATC licenses. Legislative legalization efforts stalled in March 2019 when Senate President Stephen Sweeney acknowledged insufficient votes for passage. The legislature pivoted to a constitutional amendment strategy, placing Public Question 1 on the November 2020 ballot asking voters: "Do you approve amending the Constitution to legalize a controlled form of marijuana called 'cannabis'?" On November 3, 2020, New Jersey voters approved Public Question 1 by 67% to 33%, with 2.6 million votes in favor. All 21 counties voted for approval, providing a clear mandate for implementation.

Regulatory Framework Development (2021)

The legislature passed enabling legislation on December 17, 2020, which Governor Murphy signed on February 22, 2021. The Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (CREAMMA) established the five-member Cannabis Regulatory Commission as an independent agency within the Department of Treasury. CREAMMA created a comprehensive regulatory structure including: - Class 1 through Class 6 license types covering cultivation, manufacturing, wholesale, distribution, retail, and delivery - Social equity provisions prioritizing applicants from Impact Zones (census tracts with arrest rates 120% above state average) - Municipal opt-in requirements allowing local governments to prohibit or limit cannabis businesses - A 6.625% state sales tax with no additional excise tax on adult-use sales - Vertical integration permissions allowing single entities to hold multiple license types The CRC appointed Jeff Brown as Executive Director in March 2021 and spent 13 months developing comprehensive regulations, holding 12 public hearings, and processing initial license applications.

Adult-Use Launch (2022)

New Jersey's adult-use market opened on April 21, 2022, with 13 dispensaries authorized to begin recreational sales. The initial launch included seven MSO-operated locations and six independent operators, all converting from existing medical ATCs under conditional adult-use licenses. First-day sales exceeded $1.9 million across the 13 locations. The CRC implemented a phased rollout prioritizing existing medical operators to prevent supply shortages for patients. New adult-use-only retail licenses did not begin approval until August 2022, with the first new dispensary opening in Bloomfield on December 15, 2022.

Market Maturation (2023-2026)

The market expanded rapidly through 2023 and 2024 as the CRC approved additional licenses. By December 2023, 108 dispensaries operated statewide, generating $1.6 billion in annual sales. The wholesale market developed with 52 licensed cultivators and 89 manufacturers creating a competitive supply chain. Municipal adoption accelerated as tax revenue benefits became apparent. Towns authorizing cannabis operations increased from 103 in April 2022 to 321 by April 2026. Major municipalities including Newark, Jersey City, Trenton, and Camden authorized multiple dispensaries, while suburban communities remained divided. Market dynamics shifted in 2024-2025 as wholesale prices declined 62% from launch levels, driven by cultivation capacity outpacing retail expansion. The CRC responded by accelerating retail license approvals, issuing 38 new dispensary licenses in 2025 alone. By May 2026, 146 licensed dispensaries operated across the state.

Key Players

New Jersey Cannabis Regulatory Commission

The five-member CRC holds exclusive authority over all cannabis licensing, enforcement, and rulemaking in New Jersey. Governor Murphy appointed Dianna Houenou as Chair in November 2021, replacing Jeff Brown who became Executive Director. The Commission operates with a $24 million annual budget funded by license fees and regulatory assessments. Commissioners serve five-year staggered terms and include representatives with expertise in public health, law enforcement, social justice, and business regulation. The CRC has issued 52 cultivation licenses, 89 manufacturer licenses, 146 retail licenses, 12 wholesale licenses, and 7 delivery licenses as of May 2026. The agency processes approximately 200 new applications monthly and conducts quarterly compliance inspections of all licensed facilities.

Multi-State Operators

Curaleaf operates 16 dispensaries across New Jersey under the Curaleaf brand, making it the state's largest retailer by location count. The Wakefield, Massachusetts-based MSO acquired Grassroots in 2020, inheriting three New Jersey medical licenses. Curaleaf's Bellmawr cultivation facility spans 210,000 square feet, producing approximately 45,000 pounds annually. Verano Holdings operates nine dispensaries under the Zen Leaf brand and maintains a 285,000-square-foot cultivation facility in Vineland. The Chicago-based MSO entered New Jersey through its 2018 acquisition of Alternative Medicine New Jersey, one of the original six medical ATCs. TerrAscend operates six dispensaries under The Apothecarium brand and cultivates at a 140,000-square-foot facility in Boonton. The company reported $89 million in New Jersey revenue for 2025. Ascend Wellness Holdings operates four dispensaries and a 125,000-square-foot cultivation facility in Rochelle Park. The company focuses on house brands including Ozone and Simply Herb.

Independent Operators

Acreage Holdings, though publicly traded, operates as a regional player with three New Jersey dispensaries under The Botanist brand. The company's 75,000-square-foot cultivation facility in Egg Harbor Township supplies its retail locations. Justice Grown, a social equity operator founded by former NFL player Ricky Williams and entrepreneur Calvin Stovall, opened New Jersey's first Black-owned dispensary in Montclair in March 2023. The company represents the CRC's social equity licensing priority.

Advocacy and Opposition

The New Jersey Cannabis Industry Association (NJCIA), founded in 2019, represents over 200 licensed operators and ancillary businesses. Executive Director Toni-Anne Blake advocates for regulatory reforms including interstate commerce pilot programs and 280E tax relief. Smart Approaches to Marijuana (SAM) New Jersey, led by state director Luke Niforatos, opposes market expansion and advocates for stricter potency limits and advertising restrictions. The organization testified against 12 municipal authorization ordinances in 2025. The American Civil Liberties Union of New Jersey (ACLU-NJ) monitors social equity implementation and expungement progress. Legal Director Jeanne LoCicero testified before the CRC in March 2026 regarding concerns about insufficient Impact Zone operator representation among licensees.

Legal and Regulatory Framework

New Jersey's cannabis program operates under a three-tier legal structure: constitutional authorization via the November 2020 amendment, statutory framework through CREAMMA, and administrative regulations codified at N.J.A.C. 17:30. The constitutional amendment, approved as Public Question 1, added Article I, Paragraph 23 to the New Jersey Constitution, legalizing cannabis for adults 21 and older and directing the legislature to establish regulatory structures. This constitutional foundation prevents legislative repeal without another voter referendum. The Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (N.J.S.A. 24:6I-31 et seq.) establishes the Cannabis Regulatory Commission's authority, license types, social equity provisions, and tax structure. Key statutory provisions include: Section 24:6I-35 authorizes six license classes: Class 1 (cultivator), Class 2 (manufacturer), Class 3 (wholesaler), Class 4 (distributor), Class 5 (retailer), and Class 6 (delivery). Entities may hold multiple license types, enabling vertical integration. Section 24:6I-36 establishes Impact Zones as census tracts where cannabis-related arrests exceeded 120% of the state average between 2010-2018. The CRC identified 327 Impact Zones across 71 municipalities. Social equity applicants from Impact Zones receive expedited review, reduced fees, and technical assistance. Section 24:6I-38 requires municipal authorization before the CRC may issue licenses within a jurisdiction. Municipalities may pass ordinances prohibiting all cannabis businesses, limiting license types, or capping license numbers. This provision created a patchwork of local regulations across New Jersey's 565 municipalities. Section 24:6I-39 establishes the Cannabis Regulatory Fund, funded by license fees and 1% of gross revenue from licensed businesses. The fund finances CRC operations and social equity programs. Administrative regulations at N.J.A.C. 17:30 span over 400 pages covering application requirements, operational standards, testing protocols, packaging rules, and enforcement procedures. Key regulatory provisions include: N.J.A.C. 17:30-9.10 requires all cannabis products undergo testing for potency, pesticides, heavy metals, microbials, and mycotoxins at independent ISO-17025 accredited laboratories. The CRC licenses 11 testing facilities as of May 2026. N.J.A.C. 17:30-11.3 limits THC content to 1,000 mg per package for edibles and 1,000 mg per container for concentrates. Individual edible servings may not exceed 10 mg THC. N.J.A.C. 17:30-12.2 mandates child-resistant packaging, opaque containers, and warning labels on all products. Labels must include THC/CBD content, serving size, and the statement "This product contains cannabis and is intended for use by adults 21 years of age and older." Federal law creates ongoing conflicts despite state legalization. Cannabis remains a Schedule I controlled substance under 21 U.S.C. § 812, making cultivation, distribution, and possession federal felonies punishable by up to five years imprisonment for first offenses. The Rohrabacher-Farr Amendment (renewed annually since 2014) prohibits the Department of Justice from using funds to prevent states from implementing medical cannabis laws, but provides no protection for adult-use programs. Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses, limiting deductions to cost of goods sold. New Jersey operators face effective federal tax rates of 70-80% despite state-legal operations. The Bank Secrecy Act and federal money laundering statutes (18 U.S.C. § 1956-1957) create liability for financial institutions serving cannabis businesses. Most New Jersey operators rely on state-chartered credit unions or maintain cash-intensive operations despite the 2014 FinCEN guidance providing limited safe harbor.

State-by-State Context: Northeast Regional Landscape

New Jersey's cannabis market operates within a rapidly evolving Northeast regional landscape where five of six neighboring states have legalized adult-use cannabis, creating both competitive pressures and interstate commerce opportunities currently prohibited under federal law.

New York

New York legalized adult-use cannabis through the Marijuana Regulation and Taxation Act on March 31, 2021, but delayed retail launch until December 2022. As of May 2026, New York operates 287 licensed dispensaries across the state, with 89 in New York City alone. The state's Office of Cannabis Management prioritizes social equity through its Conditional Adult-Use Retail Dispensary (CAURD) program, reserving initial licenses for justice-involved applicants. New York's larger population (19.8 million vs. New Jersey's 9.3 million) and higher retail density create competitive pressure for New Jersey border dispensaries. Wholesale prices in New York average $1,650 per pound, approximately 14% higher than New Jersey rates.

Pennsylvania

Pennsylvania operates a medical-only program serving 467,000 registered patients as of April 2026, with no adult-use legalization. The state's medical program, launched in 2018, includes 208 dispensaries and 25 grower-processors. Pennsylvania residents frequently cross into New Jersey for adult-use purchases, though interstate transport remains federally illegal. Pennsylvania Governor Josh Shapiro proposed adult-use legalization in his 2025 budget address, but the Republican-controlled legislature has not advanced enabling legislation.

Connecticut

Connecticut launched adult-use sales on January 10, 2023, under regulations administered by the Department of Consumer Protection. The state operates 54 dispensaries as of May 2026, concentrated in Hartford, New Haven, and Fairfield counties. Connecticut's 6.35% sales tax plus local option taxes create a combined rate up to 9.35%, higher than New Jersey's 6.625% rate. Connecticut's smaller market (annual sales of $380 million in 2025) and limited dispensary count drive some residents to New Jersey border locations.

Delaware

Delaware legalized adult-use possession and home cultivation on April 23, 2023, but has not yet launched retail sales. The state's Division of Alcohol and Tobacco Enforcement continues developing regulations for commercial sales expected to begin in late 2026. Delaware's medical program serves 8,200 patients through four compassion centers.

Massachusetts

Massachusetts launched adult-use sales in November 2018, making it the first East Coast state with operational retail. The state operates 403 dispensaries as of May 2026, generating $1.8 billion in annual sales. Massachusetts' mature market and competitive wholesale pricing (averaging $1,200 per pound) provide a benchmark for New Jersey operators. The Cannabis Control Commission oversees all licensing and enforcement.

Maryland

Maryland launched adult-use sales on July 1, 2023, converting existing medical dispensaries to dual-license operations. The state operates 127 dispensaries serving both medical patients and adult-use consumers. Maryland's 9% cannabis sales tax, higher than New Jersey's rate, creates price advantages for Garden State operators competing for regional market share.

Market and Business Implications

New Jersey's cannabis market generated $1.9 billion in total sales during the 12 months ending April 2026, with adult-use sales comprising $1.67 billion (88%) and medical sales $230 million (12%). The market supports approximately 12,000 direct employees across cultivation, manufacturing, retail, and ancillary operations. Wholesale dynamics shifted dramatically from launch through 2026. Wholesale flower prices peaked at $3,800 per pound in April 2022 when limited cultivation capacity constrained supply. As the CRC approved additional cultivation licenses and existing facilities expanded production, wholesale prices declined to $2,400 per pound by December 2023, $1,650 per pound by December 2024, and $1,450 per pound by March 2026. This 62% decline compressed margins across the supply chain. Cultivators responded by increasing production efficiency and scale. The average New Jersey cultivation facility produced 8,200 pounds annually in 2023, increasing to 11,400 pounds in 2025 as operators optimized environmental controls, genetics, and cultivation techniques. Cost of production declined from $420 per pound in 2023 to $310 per pound in 2025 for efficient operators. Manufacturers faced margin pressure as wholesale flower costs declined more slowly than retail prices. Wholesale concentrate prices fell from $18 per gram in April 2022 to $7.50 per gram in March 2026. Edible wholesale prices declined from $0.85 per 10mg serving to $0.35 per serving over the same period. Manufacturers responded by launching house brands, direct-to-retail programs, and value-oriented product lines. Retail economics vary significantly by location, format, and operational efficiency. High-traffic urban dispensaries in Newark, Jersey City, and Hoboken generate average monthly revenue of $850,000 to $1.2 million, while suburban locations average $320,000 to $480,000 monthly. Retail gross margins declined from 48% at launch to 38% in 2025 as wholesale prices fell and competitive pressure limited retail price increases. The May 2026 dispute between Elmwood Park and Hackensack operators highlights intensifying competition for wholesale supply relationships. According to the complaint filed with the CRC, an Elmwood Park dispensary alleged that a Hackensack competitor pressured shared wholesale suppliers to terminate supply agreements, creating inventory shortages. The CRC opened an investigation under N.J.A.C. 17:30-19.5, which prohibits anticompetitive practices including exclusive dealing arrangements that substantially lessen competition. Multi-state operators dominate New Jersey market share, with the top five MSOs controlling approximately 58% of retail sales as of Q1 2026. Curaleaf leads with 14.2% market share, followed by Verano (12.8%), TerrAscend (11.1%), Ascend Wellness (10.4%), and Acreage Holdings (9.5%). Independent operators collectively hold 42% market share but face capital constraints limiting expansion. Capital markets activity in New Jersey cannabis intensified through 2024-2025 despite federal prohibition. Private equity firms including Poseidon Asset Management, Tuatara Capital, and Chicago Atlantic Real Estate Finance provided over $340 million in debt and equity financing to New Jersey operators in 2025. Typical debt facilities carry interest rates of 12-16% with 2-3 year terms, reflecting federal illegality risk premiums. Merger and acquisition activity accelerated in 2025-2026 as smaller operators sought liquidity and MSOs pursued consolidation. Notable transactions included Curaleaf's acquisition of three independent New Jersey dispensaries for $47 million in August 2025 and Verano's purchase of a 140,000-square-foot cultivation facility in Vineland for $28 million in January 2026. Section 280E tax burdens create significant cash flow challenges. New Jersey operators pay federal income tax on gross profit (revenue minus cost of goods sold) without deductions for rent, salaries, marketing, or other operating expenses. A dispensary generating $5 million in annual revenue with $2 million in cost of goods sold and $2.4 million in operating expenses faces federal tax of approximately $900,000 (35% of $3 million gross profit), despite only $600,000 in actual pre-tax income. This creates effective federal tax rates of 70-80% for profitable operators. Banking access remains limited despite state legality. Approximately 68% of New Jersey cannabis operators maintain accounts at state-chartered credit unions including Affinity Federal Credit Union and Garden State Federal Credit Union, which accept cannabis clients under FinCEN guidance. The remaining 32% operate cash-intensive businesses, creating security risks and operational inefficiencies. The SAFE Banking Act, which would provide federal safe harbor for financial institutions serving state-legal cannabis businesses, passed the House seven times since 2019 but has not advanced in the Senate.

What Experts Say

Industry analysts, regulators, and operators provide divergent perspectives on New Jersey's market trajectory and competitive dynamics. Edmund DeVeaux, president of the New Jersey Cannabis Industry Association, said in an April 2026 interview with NJ Cannabis Insider that wholesale price compression will continue through 2027 as cultivation capacity exceeds retail demand. DeVeaux stated that the CRC should prioritize retail license approvals over additional cultivation licenses to rebalance supply and demand. He projected wholesale flower prices could decline to $1,100-1,200 per pound by year-end 2026. Dianna Houenou, CRC Chair, said during a March 2026 commission meeting that the agency remains committed to social equity licensing despite slower-than-expected Impact Zone operator participation. According to Houenou, only 23% of approved licenses have gone to social equity applicants, below the CRC's 30% target. She announced a new technical assistance program providing business planning support and access to capital for Impact Zone applicants. Scott Rudder, president of the New Jersey Cannabis Trade Association, said in a February 2026 statement that anticompetitive practices including exclusive dealing arrangements and supply chain manipulation threaten independent operators. Rudder called for enhanced CRC enforcement of existing anticompetitive conduct prohibitions and consideration of market concentration limits. Tahir Johnson, founder of social equity operator Simply Pure Trenton, said in a January 2026 interview with ROI-NJ that access to capital remains the primary barrier for Impact Zone operators. According to Johnson, traditional lenders refuse cannabis financing due to federal illegality, while private equity firms demand equity stakes of 40-60%, diluting social equity ownership. Johnson advocated for state-backed loan programs similar to Illinois' Cannabis Social Equity Loan Program. Toni-Anne Blake, executive director of the New Jersey Cannabis Industry Association, said in testimony before the Assembly Oversight, Reform and Federal Relations Committee in December 2025 that Section 280E creates an existential threat to operator profitability. Blake presented data showing that 280E increases effective federal tax rates to 70-85% for profitable operators, making New Jersey cannabis businesses among the most heavily taxed in any industry. She urged the legislature to pass a resolution supporting federal cannabis rescheduling or descheduling. Andrew Kahn, a partner at Porzio, Bromberg & Newman representing cannabis clients, said in a March 2026 legal analysis that the Elmwood Park supply dispute could establish important precedent regarding vertical integration limits and anticompetitive conduct enforcement. According to Kahn, if the CRC finds that vertically integrated operators improperly leveraged cultivation assets to disadvantage retail competitors, the agency may impose structural remedies including divestiture requirements or supply agreement mandates.

What's Next

New Jersey's cannabis market faces several critical decision points and developments through late 2026 and 2027 that will shape competitive dynamics, regulatory evolution, and market structure. The CRC will rule on the Elmwood Park anticompetitive conduct complaint by July 2026, according to the agency's standard 60-day investigation timeline. If the commission finds violations of N.J.A.C. 17:30-19.5, potential remedies include license suspension, civil penalties up to $50,000 per violation, and structural relief such as mandatory supply agreements or vertical integration restrictions. A finding of anticompetitive conduct could prompt broader rulemaking to address market concentration and vertical integration limits. The commission plans to release a comprehensive market study in September 2026 analyzing supply-demand balance, pricing trends, and market concentration. Executive Director Jeff Brown announced the study during an April 2026 stakeholder meeting, stating that findings will inform 2027 licensing priorities. Industry observers expect the study to recommend slowing cultivation license approvals while accelerating retail licensing to address wholesale oversupply. Federal cannabis rescheduling remains a wildcard for New Jersey operators. The Drug Enforcement Administration published a Notice of Proposed Rulemaking in May 2024 proposing to reschedule cannabis from Schedule I to Schedule III under 21 U.S.C. § 812. The DEA held administrative law judge hearings through late 2025, with a final rule expected in late 2026 or early 2027. Rescheduling to Schedule III would eliminate Section 280E tax burdens, potentially increasing operator profitability by 30-40%. However, rescheduling would not legalize cannabis federally or resolve banking access issues. Interstate commerce pilot programs may emerge in 2027 if federal enforcement priorities shift. The U.S. Department of Justice issued updated cannabis enforcement guidance in March 2026 stating that the department will not prioritize enforcement against state-legal cannabis businesses operating in compliance with robust regulatory systems. Some industry advocates interpret this guidance as creating space for interstate commerce pilot programs between states with compatible regulatory frameworks. New Jersey, New York, and Connecticut have discussed forming a regional compact to allow licensed interstate transfers, though no formal proposal has advanced. Municipal authorization will continue expanding as tax revenue benefits become apparent. The New Jersey League of Municipalities reported in April 2026 that towns with authorized cannabis operations collected an average of $1.2 million in transfer taxes and licensing fees in 2025. This revenue data is driving reconsideration in previously prohibitionist communities. Industry analysts project that 380-400 of New Jersey's 565 municipalities will authorize cannabis operations by December 2027, up from 321 in April 2026. The CRC plans to begin accepting applications for consumption lounge licenses in Q4 2026, according to the agency's 2026 regulatory roadmap. Consumption lounges, authorized under CREAMMA but not yet implemented, will allow on-site cannabis consumption in licensed establishments. The commission expects to approve 15-20 consumption lounge licenses in 2027, concentrated in urban entertainment districts. Delivery service expansion will accelerate through 2027 as the CRC approves additional Class 6 delivery licenses. Only seven delivery licenses have been issued as of May 2026, but the commission received 89 delivery applications in Q1 2026. Delivery services face municipal authorization requirements similar to dispensaries, limiting operational territories. The CRC is considering statewide delivery licenses that would allow service across all municipalities that have authorized cannabis operations.

Further Reading

• Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (CREAMMA) - Full statutory text: https://www.njleg.state.nj.us/bill-search/2020/A21
• New Jersey Cannabis Regulatory Commission official website and regulations: https://www.nj.gov/cannabis/
• Administrative regulations at N.J.A.C. 17:30 (complete regulatory code): https://www.nj.gov/cannabis/businesses/laws-and-rules/
• New Jersey Cannabis Industry Association industry reports and advocacy: https://www.njcannabisassociation.org/
• CRC monthly market data and license statistics: https://www.nj.gov/cannabis/businesses/marketplace-data/
• Controlled Substances Act, 21 U.S.C. § 812 (federal scheduling statute): https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13-subchapI-partB-sec812.htm
• Internal Revenue Code Section 280E (tax deduction prohibition): https://www.law.cornell.edu/uscode/text/26/280E
• DEA Notice of Proposed Rulemaking on cannabis rescheduling (May 2024): https://www.federalregister.gov/documents/2024/05/21/
• FinCEN guidance on cannabis banking (2014): https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses
• New Jersey expungement and criminal justice reform data: https://www.nj.gov/cannabis/adult-personal/criminal-justice-reform/

Update — June 30, 2026: TerrAscend Expands to Five New Jersey Dispensaries

TerrAscend Corp. signed a definitive agreement to acquire its fifth dispensary location in New Jersey, according to a company announcement on June 30, 2026. The multi-state operator did not disclose the purchase price or the specific location of the dispensary, but the transaction is expected to close in the third quarter of 2026 pending regulatory approval from the New Jersey Cannabis Regulatory Commission.

The acquisition positions TerrAscend among the largest dispensary operators in New Jersey's adult-use market, which launched in April 2022. New Jersey's Alternative Treatment Center licenses permit vertical integration, allowing licensed operators to cultivate, process, and dispense cannabis products. TerrAscend currently operates four dispensaries in the state under The Apothecarium brand, with locations serving both medical patients and adult-use customers.

The expansion comes as New Jersey's cannabis market continues to mature, with statewide sales exceeding $1.9 billion in 2025 according to state data. TerrAscend's strategy of acquiring additional retail locations reflects industry consolidation trends as operators seek to maximize market share in high-population density corridors. The company's existing New Jersey cultivation and processing facilities provide supply chain advantages for supporting additional retail outlets.

For investors and operators, the transaction underscores the competitive dynamics in New Jersey's limited-license market. The state caps the number of dispensary licenses available to existing Alternative Treatment Centers, creating barriers to entry for new competitors. TerrAscend's ability to secure a fifth location strengthens its position in the nation's most densely populated state, where proximity to major metropolitan areas drives customer traffic and revenue per location.